Tubulin binding ligands and corresponding prodrug constructs
View Patent ↗A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.
1. A compound of the following Formula I′:
wherein:
R 1 through R 11 are independently selected from the group consisting of H, OH, Alkyl, Aryl, Benzyl, Amine, Halogen, Lower Alkoxy, Phosphate, Phosphoramidate, and Amino Acid Acyl, provided that at least one of R 1 , R 2 , R 3 , R 4 , or R 5 is lower alkoxy, and
X is a single covalent bond, oxygen, or a carbonyl group.
2. The compound of the Formula I′ as in claim 1 , wherein:
at least one of R 6 , R 7 , R 8 , or R 9 are lower alkoxy
and the remaining R 1 , R 2 , R 3 , R 4 through R 11 are independently selected from the group consisting of H, OH, Halogen, Amine, Alkyl, Aryl, Benzyl, Lower Alkoxy, Phosphate, Phosphoramidate, or Amino Acid Acyl; and
X is single covalent bond, oxygen, or a carbonyl group.
3. The compound of claim 2 , wherein:
R 6 or R 8 are lower alkoxy,
at least one of R 1 , R 2 , R 3 , R 4 , or R 5 is OH, amine, phosphate or phosphoramidate,
X is a single covalent bond,
and the remaining R 1 through R 11 are H.
4. The compound of claim 2 wherein:
R 6 or R 8 are lower alkoxy,
at least one of R 1 , R 2 , R 3 , R 4 , and R 5 is OH, amine, phosphate or phosphoramidate,
X is oxygen,
and the remaining R 1 through R 11 are H.
5. The compound of claim 2 , wherein:
R 6 or R 8 are lower alkoxy,
at least one of R 1 , R 2 , R 3 , R 4 , and R 5 is OH, amine, phosphate or phosphoramidate,
X is a carbonyl,
and the remaining R 1 through R 11 are H.
6. A method for treating a vascular proliferative disorder in an animal comprising administering to an animal an effective amount of a compound of Formula I
wherein:
R 1 through R 14 are independently selected from the group consisting of H, OH, Alkyl, Aryl, Benzyl, Amine, Halogen, Lower Alkoxy, Phosphate, Phosphoramidate, or Amino Acid Acyl,
is a single or double covalent bond,
Y 1 and Y 2 are H or OH when is a single covalent bond,
X 1 and X 2 are a single covalent bond, oxygen, or a carbonyl group, and
Z is O.
7. The method of claim 6 wherein the vascular proliferative disorder is characterized by the presence of malignant proliferating vasculature.
8. The method of claim 7 wherein the malignant proliferating vasculature is associated with a tumor or other neoplastic disease.
9. The method of claim 6 wherein the vascular proliferative disorder is characterized by the presence of nonmalignant proliferating vasculature.
10. The method of claim 9 wherein the nonmalignant proliferating vasculature is associated with an ocular disease selected from the group consisting of wet or age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, diabetic molecular edema, uveitis, or corneal neovascularization.
11. The method of claim 9 wherein the nonmalignant proliferating vasculature is associated with a nonocular disease state from selected from the group consisting of psoriasis, rheumatoid arthritis, atheroma, restenosis, Kaposi's sarcoma, haemangioma, or inflammatory disease.
12. A method for selectively reducing the flow of blood to at least a portion of a neoplastic region, comprising administering an effective amount of a compound the following Formula I:
wherein:
R 1 through R 14 are independently selected from the group consisting of H, OH, Alkyl, Aryl, Benzyl, Amine, Halogen, Lower Alkoxy, Phosphate, Phosphoramidate, or Amino Acid Acyl,
is a single or double covalent bond,
Y 1 and Y 2 are H or OH when is a single covalent bond,
X 1 and X 2 are a single covalent bond, oxygen, or a carbonyl group, and
Z is O,
thereby causing substantial necrosis of tissue in the neoplastic region without substantial necrosis of tissue in adjoining regions.
13. The method of claim 12 wherein the reduction in tumor blood flow is reversible such that normal tumor blood flow is restored following cessation of treatment.
14. A method for treating neoplastic disease in an animal comprising administering to an animal an antiproliferative amount of a compound of Formula I:
wherein:
R 1 through R 14 are independently selected from the group consisting of H, OH, Alkyl, Aryl, Benzyl, Amine, Halogen, Lower Alkoxy, Phosphate, Phosphoramidate, or Amino Acid Acyl,
is a single or double covalent bond,
Y 1 and Y 2 are H or OH when is a single covalent bond,
X 1 and X 2 are a single covalent bond, oxygen, or a carbonyl group, and
Z is O.
15. The method of claim 14 wherein the compound has the direct result of causing tumor cell cytotoxicity due to inhibition of mitosis.
16. A method for inhibiting tubulin polymerization by contacting a tubulin-containing system with a compound of Formula I:
wherein:
R 1 through R 14 are independently selected from the group consisting of H, OH, Alkyl, Aryl, Benzyl, Amine, Halogen, Lower Alkoxy, Phosphate, Phosphoramidate, or Amino Acid Acyl,
is a single or double covalent bond,
Y 1 and Y 2 are H or OH when is a single covalent bond,
X 1 and X 2 are a single covalent bond, oxygen, or a carbonyl group, and
Z is O.
17. The method of claim 16 wherein said system is a tumor cell.
18. A pharmaceutical formulation containing a compound of Formula I:
wherein:
R 1 through R 14 are independently selected from the group consisting of H, OH, Alkyl, Aryl, Benzyl, Amine, Halogen, Lower Alkoxy, Phosphate, Phosphoramidate, or Amino Acid Acyl, provided that at least one of R 1 , R 2 , R 3 , R 4 , or R 5 is lower alkoxy,
X is a single covalent bond, oxygen, or a carbonyl group,
and a pharmaceutically suitable carrier.
19. The compound of claim 1 , wherein R 3 is methoxy.
20. The compound of claim 1 , wherein R 8 is methoxy.
21. A compound of the formula:
22. A compound of the formula:
23. A compound of the formula:
24. A compound of the formula:
25. A method for treating a vascular proliferative disorder in an animal comprising administering to an animal an effective amount of a compound of Formula I′:
wherein:
R 1 through R 11 are independently selected from the group consisting of H, OH, Alkyl, Aryl, Benzyl, Amine, Halogen, Lower Alkoxy, Phosphate, Phosphoramidate, and Amino Acid Acyl, provided that at least one of R 1 , R 2 , R 3 , R 4 , or R 5 is lower alkoxy, and
X is a single covalent bond, oxygen, or a carbonyl group.
26. A method for selectively reducing the flow of blood to at least a portion of a neoplastic region, comprising administering an effective amount of a compound the following Formula I′:
wherein:
R 1 through R 11 , are independently selected from the group consisting of H, OH, Alkyl, Aryl, Benzyl, Amine, Halogen, Lower Alkoxy, Phosphate, Phosphoramidate, and Amino Acid Acyl, provided that at least one of R 1 , R 2 , R 3 , R 4 , or R 5 is lower alkoxy, and
X is a single covalent bond, oxygen, or a carbonyl group.
27. A method for treating neoplastic disease in an animal comprising administering to an animal an antiproliferative amount of a compound of Formula I′:
wherein:
R 1 through R 11 are independently selected from the group consisting of H, OH, Alkyl, Aryl, Benzyl, Amine, Halogen, Lower Alkoxy, Phosphate, Phosphoramidate, and Amino Acid Acyl, provided that at least one of R 1 , R 2 , R 3 , R 4 , or R 5 is lower alkoxy, and
X is a single covalent bond, oxygen, or a carbonyl group.
28. A method for inhibiting tubulin polymerization by contacting a tubulin-containing system with a compound of Formula I′:
wherein:
R 1 through R 11 are independently selected from the group consisting of H, OH, Alkyl, Aryl, Benzyl, Amine, Halogen, Lower Alkoxy, Phosphate, Phosphoramidate, and Amino Acid Acyl, provided that at least one of R 1 , R 2 , R 3 , R 4 , or R 5 is lower alkoxy, and
X is a single covalent bond, oxygen, or a carbonyl group.